Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma
NCT ID: NCT05847569
Last Updated: 2026-02-03
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE2
Total Enrollment
62 participants
Study Classification
INTERVENTIONAL
Study Start Date
2024-01-04
Study Completion Date
2034-06-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This phase II trial tests alternate doses and dosing schedules of belantamab mafodotin in treating patients with triple-class multiple myeloma that has come back (after a period of improvement) (recurrent) and/or does not respond to treatment (or that has not responded to previous treatment) (refractory). Belantamab mafodotin is a monoclonal antibody, belantamab, linked to a chemotherapy drug, mafodotin. Belantamab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as BCMA receptors, and delivers mafodotin to kill them. This trial may help researchers determine if alternate doses and dosing schedules work better in preventing certain side effects, such as eye toxicity, and treating patients with recurrent or refractory multiple myeloma.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory
NCT05581875
Multiple Myeloma
Multiple Myeloma in Relapse
Neoplasms
+6 more
NOT_YET_RECRUITING
PHASE1/PHASE2
A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody
NCT03525678
Multiple Myeloma
COMPLETED
PHASE2
Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT04126200
Multiple Myeloma
ACTIVE_NOT_RECRUITING
PHASE2
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM
NCT07217119
Multiple Myeloma
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma
NCT04892264
Plasma Cell Myeloma
Recurrent Plasma Cell Myeloma
Refractory Plasma Cell Myeloma
TERMINATED
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
PRIMARY OBJECTIVE:
I. To assess the grade 3/4 keratopathy-free rate at the time of dose #4 of an alternative dose/dosing schedule of belantamab mafodotin in patients with relapsed or refractory multiple myeloma (RRMM).
SECONDARY OBJECTIVES:
I. To assess the overall response rate (ORR; partial response or better) of an alternative dose/dosing schedule of belantamab mafodotin in patients with RRMM.
II. To assess the safety of an alternative dose/dosing schedule of belantamab mafodotin in patients with RRMM.
III. To assess the time to progression (TTP) of an alternative dose/dosing schedule of belantamab mafodotin in patients with RRMM.
IV. To assess the progression free survival (PFS) with an alternative dose/dosing schedule of belantamab mafodotin in patients with RRMM.
V. To assess the overall survival (OS) with an alternative dose/dosing schedule of belantamab mafodotin in patients with RRMM.
VI. To assess the minimal residual disease (MRD) negativity rate in patients who have achieved a complete response (CR) with an alternative dose/dosing schedule of belantamab mafodotin.
CORRELATIVE AND PHARMACODYNAMIC RESEARCH OBJECTIVES:
I. To assess the association of pre-treatment serum BCMA levels as well as serum BCMA levels throughout treatment with ORR and PFS to an alternative treatment schedule of belantamab mafodotin.
II. To assess the pharmacokinetics of this alternative dose/dosing schedule of belantamab mafodotin.
OUTLINE: Patients are randomized to 1 of 2 groups.
GROUP I: Patients receive low dose belantamab mafodotin intravenously (IV) on day 1 of each cycle. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. All patients undergo a computed tomography (CT) scan, a magnetic resonance image (MRI) scan, or a positron emission tomography (PET)/CT scan during screening and patients with plasmacytoma (a multiple myeloma \[MM\] tumor in bone or soft tissue) also undergo imaging scans on study. Patients undergo bone marrow aspirate and biopsy during screening and on study as well as collection of blood samples throughout the trial.
GROUP II: Patients receive belantamab mafodotin IV on day 1. Cycle repeats at 3 weeks for the next cycle and then every 6 weeks for subsequent cycles in the absence of disease progression or unacceptable toxicity. All patients undergo a CT scan, a MRI scan, or a PET/CT scan during screening and patients with plasmacytoma (a MM tumor in bone or soft tissue) also undergo imaging scans on study. Patients undergo bone marrow aspirate and biopsy during screening and on study as well as collection of blood samples throughout the trial.
After completion of trial treatment, patients are followed up every 12 weeks for up to 5 years.
I. To assess the grade 3/4 keratopathy-free rate at the time of dose #4 of an alternative dose/dosing schedule of belantamab mafodotin in patients with relapsed or refractory multiple myeloma (RRMM).
SECONDARY OBJECTIVES:
I. To assess the overall response rate (ORR; partial response or better) of an alternative dose/dosing schedule of belantamab mafodotin in patients with RRMM.
II. To assess the safety of an alternative dose/dosing schedule of belantamab mafodotin in patients with RRMM.
III. To assess the time to progression (TTP) of an alternative dose/dosing schedule of belantamab mafodotin in patients with RRMM.
IV. To assess the progression free survival (PFS) with an alternative dose/dosing schedule of belantamab mafodotin in patients with RRMM.
V. To assess the overall survival (OS) with an alternative dose/dosing schedule of belantamab mafodotin in patients with RRMM.
VI. To assess the minimal residual disease (MRD) negativity rate in patients who have achieved a complete response (CR) with an alternative dose/dosing schedule of belantamab mafodotin.
CORRELATIVE AND PHARMACODYNAMIC RESEARCH OBJECTIVES:
I. To assess the association of pre-treatment serum BCMA levels as well as serum BCMA levels throughout treatment with ORR and PFS to an alternative treatment schedule of belantamab mafodotin.
II. To assess the pharmacokinetics of this alternative dose/dosing schedule of belantamab mafodotin.
OUTLINE: Patients are randomized to 1 of 2 groups.
GROUP I: Patients receive low dose belantamab mafodotin intravenously (IV) on day 1 of each cycle. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. All patients undergo a computed tomography (CT) scan, a magnetic resonance image (MRI) scan, or a positron emission tomography (PET)/CT scan during screening and patients with plasmacytoma (a multiple myeloma \[MM\] tumor in bone or soft tissue) also undergo imaging scans on study. Patients undergo bone marrow aspirate and biopsy during screening and on study as well as collection of blood samples throughout the trial.
GROUP II: Patients receive belantamab mafodotin IV on day 1. Cycle repeats at 3 weeks for the next cycle and then every 6 weeks for subsequent cycles in the absence of disease progression or unacceptable toxicity. All patients undergo a CT scan, a MRI scan, or a PET/CT scan during screening and patients with plasmacytoma (a MM tumor in bone or soft tissue) also undergo imaging scans on study. Patients undergo bone marrow aspirate and biopsy during screening and on study as well as collection of blood samples throughout the trial.
After completion of trial treatment, patients are followed up every 12 weeks for up to 5 years.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Recurrent Multiple Myeloma
Refractory Multiple Myeloma
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group I (low dose belantamab mafodotin)
Patients receive low dose belantamab mafodotin intravenously (IV) on day 1 of each cycle. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. All patients undergo a CT scan, a MRI scan, or a PET/CT scan during screening and patients with plasmacytoma (a MM tumor in bone or soft tissue) also undergo imaging scans on study. Patients undergo bone marrow aspirate and biopsy during screening and on study as well as collection of blood samples throughout the trial.
Group Type
ACTIVE_COMPARATOR
Belantamab Mafodotin
Intervention Type
BIOLOGICAL
Given IV
Biospecimen Collection
Intervention Type
PROCEDURE
Undergo collection of blood samples
Bone Marrow Aspirate
Intervention Type
PROCEDURE
Undergo bone marrow aspirate
Bone Marrow Biopsy
Intervention Type
PROCEDURE
Undergo biopsy
Computed Tomography
Intervention Type
PROCEDURE
Undergo CT scan
Magnetic Resonance Imaging
Intervention Type
PROCEDURE
Undergo MRI scan
Positron Emission Tomography
Intervention Type
PROCEDURE
Undergo PET/CT scan
Group II (low dose and high dose belantamab mafodotin)
Patients receive belantamab mafodotin IV on day 1. Cycle repeats at 3 weeks for the next cycle and then every 6 weeks for subsequent cycles in the absence of disease progression or unacceptable toxicity. All patients undergo a CT scan, a MRI scan, or a PET/CT scan during screening and patients with plasmacytoma (a MM tumor in bone or soft tissue) also undergo imaging scans on study. Patients undergo bone marrow aspirate and biopsy during screening and on study as well as collection of blood samples throughout the trial.
Group Type
EXPERIMENTAL
Belantamab Mafodotin
Intervention Type
BIOLOGICAL
Given IV
Biospecimen Collection
Intervention Type
PROCEDURE
Undergo collection of blood samples
Bone Marrow Aspirate
Intervention Type
PROCEDURE
Undergo bone marrow aspirate
Bone Marrow Biopsy
Intervention Type
PROCEDURE
Undergo biopsy
Computed Tomography
Intervention Type
PROCEDURE
Undergo CT scan
Magnetic Resonance Imaging
Intervention Type
PROCEDURE
Undergo MRI scan
Positron Emission Tomography
Intervention Type
PROCEDURE
Undergo PET/CT scan
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Belantamab Mafodotin
Given IV
Intervention Type
BIOLOGICAL
Biospecimen Collection
Undergo collection of blood samples
Intervention Type
PROCEDURE
Bone Marrow Aspirate
Undergo bone marrow aspirate
Intervention Type
PROCEDURE
Bone Marrow Biopsy
Undergo biopsy
Intervention Type
PROCEDURE
Computed Tomography
Undergo CT scan
Intervention Type
PROCEDURE
Magnetic Resonance Imaging
Undergo MRI scan
Intervention Type
PROCEDURE
Positron Emission Tomography
Undergo PET/CT scan
Intervention Type
PROCEDURE
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Belantamab Mafodotin-blmf
Blenrep
GSK2857916
J6M0-mcMMAF
Biological Sample Collection
Biospecimen Collected
Specimen Collection
BONE MARROW, LIQUID
Human Bone Marrow Aspirate
Biopsy of Bone Marrow
Biopsy, Bone Marrow
CAT
CAT Scan
Computed Axial Tomography
Computerized Axial Tomography
Computerized axial tomography (procedure)
Computerized Tomography
CT
CT Scan
tomography
Computerized Tomography (CT) scan
Magnetic Resonance
Magnetic resonance imaging (procedure)
Magnetic Resonance Imaging Scan
Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance
MR
MR Imaging
MRI
MRI Scan
NMR Imaging
NMRI
Nuclear Magnetic Resonance Imaging
Magnetic Resonance Imaging (MRI)
Medical Imaging, Positron Emission Tomography
PET
PET Scan
Positron emission tomography (procedure)
Positron Emission Tomography Scan
Positron-Emission Tomography
proton magnetic resonance spectroscopic imaging
PT
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age \>= 18 years
* Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, 2
* Histologically or cytologically confirmed diagnosis of multiple myeloma (MM), as defined in International Myeloma Working Group (IMWG) criteria, and:
* If patients have undergone stem cell transplantation (SCT), day 0 of SCT must be \> 100 days prior to registration to be eligible for the study
* Has had disease progression after \>= 3 prior lines of anti-myeloma treatments including one proteasome inhibitor (eg. bortezomib, carfilzomib or ixazomib), one immunomodulatory agent (eg.thalidomide, lenalidomide or pomalidomide) and one anti-CD38 monoclonal antibody (eg.daratumumab or isatuximab)
* Prior non-belantamab mafodotin anti-BCMA agent exposure is allowed; patients with prior treatment with an anti-BCMA chimeric antigen receptor (CAR)-T or bispecific antibody will be allowed to participate in the study
* Has measurable disease with at least one of the following:
* Serum M-protein \>= 0.5 g/dL (\>= 5 g/L)
* Urine M-protein \>= 200 mg/24 h
* Serum free light chain (FLC) assay: Involved FLC level \>= 10 mg/dL (\>= 100 mg/L) and an abnormal serum free light chain ratio (\< 0.26 or \> 1.65)
* Note: Patients with non-secretory disease will be allowed to participate
* Absolute neutrophil count \>= 0.75 x 10\^9/L (=\< 28 days prior to registration)
* Without growth factor support, blood transfusion, or platelet stimulating agents for the past 14 days, excluding erythropoietin
* Hemoglobin \>= 7.0 g/dL (=\< 28 days prior to registration)
* Without growth factor support, blood transfusion, or platelet stimulating agents for the past 14 days, excluding erythropoietin
* Platelets \>= 50 x 10\^9/L (=\< 28 days prior to registration)
* Without growth factor support, blood transfusion, or platelet stimulating agents for the past 14 days, excluding erythropoietin
* Total bilirubin =\< 2.0 x upper limit of normal (ULN) (=\< 28 days prior to registration); (total bilirubin \>= 2.0 x ULN is acceptable if bilirubin is fractionated and direct bilirubin is \< 35%)
* Alanine aminotransferase =\< 2.5 x ULN (=\< 28 days prior to registration)
* Aspartate transaminase =\< 2.5 x ULN (=\< 28 days prior to registration)
* Estimated glomerular filtration rate (eGFR) \>= 30 mL/min/1.73 m\^2 (=\< 28 days prior to registration)
* As calculated by Modification of Diet in Renal Disease (MDRD) formula
* Spot urine \[albumin/creatinine ratios (spot urine)\] =\< 500 mg/g (56 mg/mmol) OR urine dipstick negative/trace \[if \>1+ only eligible if confirmed =\< 500 mg/g (56 mg/mmol) by albumin/creatinine ratio (spot urine from first void)\] (=\< 28 days prior to registration)
* Negative pregnancy test done =\< 7 days prior to registration, for persons of childbearing potential only. Both females and males must agree to follow the instructions
* NOTE: If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
* Provide written informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the study protocol
* Willingness to provide mandatory blood specimens for correlative research
* Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)
* Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, 2
* Histologically or cytologically confirmed diagnosis of multiple myeloma (MM), as defined in International Myeloma Working Group (IMWG) criteria, and:
* If patients have undergone stem cell transplantation (SCT), day 0 of SCT must be \> 100 days prior to registration to be eligible for the study
* Has had disease progression after \>= 3 prior lines of anti-myeloma treatments including one proteasome inhibitor (eg. bortezomib, carfilzomib or ixazomib), one immunomodulatory agent (eg.thalidomide, lenalidomide or pomalidomide) and one anti-CD38 monoclonal antibody (eg.daratumumab or isatuximab)
* Prior non-belantamab mafodotin anti-BCMA agent exposure is allowed; patients with prior treatment with an anti-BCMA chimeric antigen receptor (CAR)-T or bispecific antibody will be allowed to participate in the study
* Has measurable disease with at least one of the following:
* Serum M-protein \>= 0.5 g/dL (\>= 5 g/L)
* Urine M-protein \>= 200 mg/24 h
* Serum free light chain (FLC) assay: Involved FLC level \>= 10 mg/dL (\>= 100 mg/L) and an abnormal serum free light chain ratio (\< 0.26 or \> 1.65)
* Note: Patients with non-secretory disease will be allowed to participate
* Absolute neutrophil count \>= 0.75 x 10\^9/L (=\< 28 days prior to registration)
* Without growth factor support, blood transfusion, or platelet stimulating agents for the past 14 days, excluding erythropoietin
* Hemoglobin \>= 7.0 g/dL (=\< 28 days prior to registration)
* Without growth factor support, blood transfusion, or platelet stimulating agents for the past 14 days, excluding erythropoietin
* Platelets \>= 50 x 10\^9/L (=\< 28 days prior to registration)
* Without growth factor support, blood transfusion, or platelet stimulating agents for the past 14 days, excluding erythropoietin
* Total bilirubin =\< 2.0 x upper limit of normal (ULN) (=\< 28 days prior to registration); (total bilirubin \>= 2.0 x ULN is acceptable if bilirubin is fractionated and direct bilirubin is \< 35%)
* Alanine aminotransferase =\< 2.5 x ULN (=\< 28 days prior to registration)
* Aspartate transaminase =\< 2.5 x ULN (=\< 28 days prior to registration)
* Estimated glomerular filtration rate (eGFR) \>= 30 mL/min/1.73 m\^2 (=\< 28 days prior to registration)
* As calculated by Modification of Diet in Renal Disease (MDRD) formula
* Spot urine \[albumin/creatinine ratios (spot urine)\] =\< 500 mg/g (56 mg/mmol) OR urine dipstick negative/trace \[if \>1+ only eligible if confirmed =\< 500 mg/g (56 mg/mmol) by albumin/creatinine ratio (spot urine from first void)\] (=\< 28 days prior to registration)
* Negative pregnancy test done =\< 7 days prior to registration, for persons of childbearing potential only. Both females and males must agree to follow the instructions
* NOTE: If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
* Provide written informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the study protocol
* Willingness to provide mandatory blood specimens for correlative research
* Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)
Exclusion Criteria
* Active plasma cell leukemia at the time of screening. Symptomatic amyloidosis, active POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal plasmaproliferative disorder, myeloma protein, and skin changes), Waldenstrom Macroglobulinemia
* Prior belantamab mafodotin therapy. However, patients with prior exposure to another non-belantamab mafodotin anti-BCMA agent such as an anti-BCMA CAR-T or anti-BCMA bispecific antibody will be allowed to participate in the study
* Systemic active infection requiring treatment
* Any unresolved toxicity \>= grade 2 from previous treatment except for alopecia, or peripheral neuropathy up to grade 2
* Any major surgery =\< 4 weeks prior to registration
* Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions (including lab abnormalities except renal impairment) that could interfere with participant's safety, obtaining informed consent or compliance to the study procedures
* Evidence of active mucosal or internal bleeding
* Current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis. Note: Stable chronic liver disease (including Gilbert's syndrome or asymptomatic gallstones) or hepatobiliary involvement of malignancy is acceptable if participant otherwise meets entry criteria
* Participants with previous or concurrent malignancies other than multiple myeloma are excluded, unless the prior malignancy has been considered medically stable for \> 2 years. The participant must not be receiving active therapy, other than hormonal therapy for this disease. NOTE: Participants with curatively treated nonmelanoma skin cancer are allowed without a 2-year restriction.
* Evidence of cardiovascular risk, including any of the following:
* Evidence of current clinically significant untreated arrhythmias, including clinically significant electrocardiogram (ECG) abnormalities including 2nd degree (Mobitz type II) or 3rd degree atrioventricular (AV) block
* History of myocardial infarction (=\< 6 months), acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting within 12 weeks of screening
* Class III or IV heart failure as defined by the New York Heart Association functional classification system \[NYHA, 1994\]
* Uncontrolled hypertension
* Known immediate or delayed hypersensitivity reaction or idiosyncratic reaction to drugs chemically related to belantamab mafodotin, or any of the components of the study treatment
* Known human immunodeficiency virus (HIV) infection, unless the participant can meet all of the following criteria:
* Established anti-retroviral therapy (ART) for at \>=4 weeks and HIV viral load \< 400 copies/mL
* CD4+ T-cell (CD4+) counts \>= 350 cells/uL
* No history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections \< 12 months prior
* Note: consideration must be given to ART and prophylactic antimicrobials that may have a drug-drug interaction and/or overlapping toxicities with belantamab mafodotin or other combination products as relevant
* Patients with hepatitis B will be excluded unless the following criteria can be met:
* If patient's serology shows hepatitis B virus core antibody (HbcAb)+ and hepatitis B surface antigen (HbsAg)-, they must have undetectable hepatitis B virus (HBV) deoxyribonucleic acid (DNA) at screening. Patients will be monitored per protocol. Antiviral treatment would be instituted if HBV DNA becomes detectable
* If patient's serology shows HBsAg+ at screen or within 3 months prior, patients must have undetectable HBV DNA at screening, must have started highly effective antiviral treatment at least 4 weeks prior to registration, and must have baseline imaging per protocol (patients with cirrhosis are excluded). Patients must remain on antiviral treatment throughout the study. Patients will be monitored per protocol
* Note: presence of hepatitis (Hep) B surface antibody (HBsAb) indicating previous vaccination will not exclude a participant.
* Positive hepatitis C antibody test result or positive hepatitis C ribonucleic acid (RNA) test result at screening or =\< 12 weeks prior to first dose of study treatment unless the participant can meet the following criteria:
* RNA test negative
* Successful anti-viral treatment (usually 8 weeks duration) is required, followed by a negative HCV RNA test after a washout period \>= 4 weeks
* Current corneal epithelial disease except for mild punctuate keratopathy
* Participant who received plasmapheresis within =\< 7 days prior to registration
* Patients who received prior allogeneic stem cell transplant
* Participant who received a live or live-attenuated vaccine =\< 30 days prior to registration. Ok to receive coronavirus disease (COVID) vaccine at any timepoint during protocol treatment
* Participant is a woman who is pregnant or lactating
* Participant who plans on wearing contact lenses during treatment with belantamab mafodotin
Lifestyle Considerations:
Contact lenses are prohibited for participants while they are receiving belantamab mafodotin treatment. Contact lens use may be restarted after belantamab mafodotin treatment is discontinued, provided a qualified eye care specialist confirm there are no other contraindications. Use of bandage contact lenses is allowed for the treatment of corneal epithelial disease as prescribed by an ophthalmologist/eye care professional.
No other lifestyle restrictions are required for participants in this study.
* Prior belantamab mafodotin therapy. However, patients with prior exposure to another non-belantamab mafodotin anti-BCMA agent such as an anti-BCMA CAR-T or anti-BCMA bispecific antibody will be allowed to participate in the study
* Systemic active infection requiring treatment
* Any unresolved toxicity \>= grade 2 from previous treatment except for alopecia, or peripheral neuropathy up to grade 2
* Any major surgery =\< 4 weeks prior to registration
* Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions (including lab abnormalities except renal impairment) that could interfere with participant's safety, obtaining informed consent or compliance to the study procedures
* Evidence of active mucosal or internal bleeding
* Current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis. Note: Stable chronic liver disease (including Gilbert's syndrome or asymptomatic gallstones) or hepatobiliary involvement of malignancy is acceptable if participant otherwise meets entry criteria
* Participants with previous or concurrent malignancies other than multiple myeloma are excluded, unless the prior malignancy has been considered medically stable for \> 2 years. The participant must not be receiving active therapy, other than hormonal therapy for this disease. NOTE: Participants with curatively treated nonmelanoma skin cancer are allowed without a 2-year restriction.
* Evidence of cardiovascular risk, including any of the following:
* Evidence of current clinically significant untreated arrhythmias, including clinically significant electrocardiogram (ECG) abnormalities including 2nd degree (Mobitz type II) or 3rd degree atrioventricular (AV) block
* History of myocardial infarction (=\< 6 months), acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting within 12 weeks of screening
* Class III or IV heart failure as defined by the New York Heart Association functional classification system \[NYHA, 1994\]
* Uncontrolled hypertension
* Known immediate or delayed hypersensitivity reaction or idiosyncratic reaction to drugs chemically related to belantamab mafodotin, or any of the components of the study treatment
* Known human immunodeficiency virus (HIV) infection, unless the participant can meet all of the following criteria:
* Established anti-retroviral therapy (ART) for at \>=4 weeks and HIV viral load \< 400 copies/mL
* CD4+ T-cell (CD4+) counts \>= 350 cells/uL
* No history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections \< 12 months prior
* Note: consideration must be given to ART and prophylactic antimicrobials that may have a drug-drug interaction and/or overlapping toxicities with belantamab mafodotin or other combination products as relevant
* Patients with hepatitis B will be excluded unless the following criteria can be met:
* If patient's serology shows hepatitis B virus core antibody (HbcAb)+ and hepatitis B surface antigen (HbsAg)-, they must have undetectable hepatitis B virus (HBV) deoxyribonucleic acid (DNA) at screening. Patients will be monitored per protocol. Antiviral treatment would be instituted if HBV DNA becomes detectable
* If patient's serology shows HBsAg+ at screen or within 3 months prior, patients must have undetectable HBV DNA at screening, must have started highly effective antiviral treatment at least 4 weeks prior to registration, and must have baseline imaging per protocol (patients with cirrhosis are excluded). Patients must remain on antiviral treatment throughout the study. Patients will be monitored per protocol
* Note: presence of hepatitis (Hep) B surface antibody (HBsAb) indicating previous vaccination will not exclude a participant.
* Positive hepatitis C antibody test result or positive hepatitis C ribonucleic acid (RNA) test result at screening or =\< 12 weeks prior to first dose of study treatment unless the participant can meet the following criteria:
* RNA test negative
* Successful anti-viral treatment (usually 8 weeks duration) is required, followed by a negative HCV RNA test after a washout period \>= 4 weeks
* Current corneal epithelial disease except for mild punctuate keratopathy
* Participant who received plasmapheresis within =\< 7 days prior to registration
* Patients who received prior allogeneic stem cell transplant
* Participant who received a live or live-attenuated vaccine =\< 30 days prior to registration. Ok to receive coronavirus disease (COVID) vaccine at any timepoint during protocol treatment
* Participant is a woman who is pregnant or lactating
* Participant who plans on wearing contact lenses during treatment with belantamab mafodotin
Lifestyle Considerations:
Contact lenses are prohibited for participants while they are receiving belantamab mafodotin treatment. Contact lens use may be restarted after belantamab mafodotin treatment is discontinued, provided a qualified eye care specialist confirm there are no other contraindications. Use of bandage contact lenses is allowed for the treatment of corneal epithelial disease as prescribed by an ophthalmologist/eye care professional.
No other lifestyle restrictions are required for participants in this study.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mayo Clinic
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ricardo D. Parrondo, M.D.
Role: PRINCIPAL_INVESTIGATOR
Mayo Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic in Florida
Jacksonville, Florida, United States
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
United States
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Related Links
Access external resources that provide additional context or updates about the study.
https://www.mayo.edu/research/clinical-trials
Mayo Clinic Clinical Trials
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2023-03039
Identifier Type: REGISTRY
Identifier Source: secondary_id
MC210812
Identifier Type: OTHER
Identifier Source: secondary_id
22-001207
Identifier Type: OTHER
Identifier Source: secondary_id
MC210812
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma
NCT05064358
ACTIVE_NOT_RECRUITING
PHASE2
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
NCT07227311
NOT_YET_RECRUITING
PHASE2
A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function
NCT04398745
ACTIVE_NOT_RECRUITING
PHASE1
Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM
NCT06655818
TERMINATED
PHASE1/PHASE2
A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma
NCT05573802
RECRUITING
PHASE1/PHASE2
Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant
NCT04876248
ACTIVE_NOT_RECRUITING
PHASE2
Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients
NCT04802356
ACTIVE_NOT_RECRUITING
PHASE2
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM
NCT07084896
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma
NCT05117008
TERMINATED
PHASE2
Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma
NCT04091126
ACTIVE_NOT_RECRUITING
PHASE1
A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT04177823
COMPLETED
PHASE1
Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma
NCT05065047
TERMINATED
PHASE1
A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment
NCT05556798
ACTIVE_NOT_RECRUITING
PHASE1
Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma
NCT06232044
SUSPENDED
PHASE1/PHASE2
Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM
NCT07150104
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma
NCT04680468
ACTIVE_NOT_RECRUITING
PHASE2
An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments
NCT03828292
COMPLETED
PHASE1
Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
NCT07285239
NOT_YET_RECRUITING
PHASE3
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
NCT04484623
ACTIVE_NOT_RECRUITING
PHASE3
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM
NCT07150091
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma
NCT05055063
RECRUITING
PHASE1
Real-World Analysis of Belantamab Mafodotin Care Patterns in Patients With Relapsed and/or Refractory Multiple Myeloma
NCT05986682
COMPLETED
Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
NCT04808037
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide
NCT05060627
RECRUITING
PHASE1/PHASE2